MERCK KGAA

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

Aspargo Labs appoints Álvaro Fernández in Spain and Dr. Marc van Unen in Germany to accelerate global expansion, leveraging their pharmaceutical industry expertise.

Aspargo Labs appoints Álvaro Fernández and Dr. Marc van Unen as General Managers in Spain and Germany to drive global expansion. Both bring extensive pharmaceutical experience to accelerate the company's international growth.

The Global Biopreservation Market is projected to grow from US$5.44 billion in 2024 to US$24.51 billion by 2033, driven by personalized medicine, biotechnology advancements, and rare disease awareness. Key players include Thermo Fisher Scientific, Cryport, Eppendorf, BioLife Solutions, Azenta, Merck KGaA, Qiagen, and Chart Industries.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, plans to acquire HUB Organoids Holding B.V. to enhance its portfolio in next-generation biology. HUB’s organoid technology accelerates drug development, reduces reliance on animal testing, and improves disease treatment understanding. The deal is expected to close by end of December 2024.

The 'Myositis - Pipeline Insight, 2024' report by ResearchAndMarkets.com offers insights into 18+ companies and 20+ pipeline drugs for Myositis, covering drug profiles, therapeutic assessments, and pipeline development activities.

The antibody production market, valued at US$ 15.6 Bn in 2023, is projected to reach US$ 30.7 Bn by 2031 with a CAGR of 7.8%, driven by advancements in bioprocessing, rising chronic disease prevalence, and increased R&D investments. Key segments include service type, sourcing type, application, industry vertical, and region. North America leads, while Asia-Pacific shows fastest growth. Market drivers include technological innovations and biologics approvals, while challenges include high production costs and regulatory hurdles. Trends include biosimilars, automation, personalized medicine, and sustainable bioprocessing.

The human organoids market is projected to grow from $1.19B in 2024 to $2.33B by 2029, at a CAGR of 14.4%. Funding and advancements in research drive market growth, with applications in drug toxicity, personalized medicine, and developmental biology. Pharmaceutical and biotech companies lead in end-user growth, while Asia-Pacific shows the fastest regional growth due to healthcare infrastructure investments and medical tourism.

SkyQuest projects the global healthcare analytical testing services market to reach USD 15.55 Billion by 2031, with a CAGR of 11.2% (2024-2031). Driving factors include outsourcing by pharmaceutical and medical device companies, increased clinical trials, and rising biosimilars emphasis. The COVID-19 pandemic also boosted demand.